These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1076 related articles for article (PubMed ID: 26928437)

  • 1. Innovation in the pharmaceutical industry: New estimates of R&D costs.
    DiMasi JA; Grabowski HG; Hansen RW
    J Health Econ; 2016 May; 47():20-33. PubMed ID: 26928437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The price of innovation: new estimates of drug development costs.
    DiMasi JA; Hansen RW; Grabowski HG
    J Health Econ; 2003 Mar; 22(2):151-85. PubMed ID: 12606142
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost of innovation in the pharmaceutical industry.
    DiMasi JA; Hansen RW; Grabowski HG; Lasagna L
    J Health Econ; 1991 Jul; 10(2):107-42. PubMed ID: 10113009
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Research and development costs for new drugs by therapeutic category. A study of the US pharmaceutical industry.
    DiMasi JA; Hansen RW; Grabowski HG; Lasagna L
    Pharmacoeconomics; 1995 Feb; 7(2):152-69. PubMed ID: 10155302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Research Spending on New Drug Approvals by the National Institutes of Health vs the Pharmaceutical Industry, 2010-2019.
    Galkina Cleary E; Jackson MJ; Zhou EW; Ledley FD
    JAMA Health Forum; 2023 Apr; 4(4):e230511. PubMed ID: 37115539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018.
    Wouters OJ; McKee M; Luyten J
    JAMA; 2020 Mar; 323(9):844-853. PubMed ID: 32125404
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Public sector replacement of privately funded pharmaceutical R&D: cost and efficiency considerations.
    Proudman D; Desai U; Gomes DA; Khomenko M; Martin S; Nellesen D; Neumann U; Grabowski H
    J Med Econ; 2024; 27(1):1253-1266. PubMed ID: 39361016
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of Sales Income and Research and Development Costs for FDA-Approved Cancer Drugs Sold by Originator Drug Companies.
    Tay-Teo K; Ilbawi A; Hill SR
    JAMA Netw Open; 2019 Jan; 2(1):e186875. PubMed ID: 30644967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After Approval.
    Prasad V; Mailankody S
    JAMA Intern Med; 2017 Nov; 177(11):1569-1575. PubMed ID: 28892524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The value of improving the productivity of the drug development process: faster times and better decisions.
    DiMasi JA
    Pharmacoeconomics; 2002; 20 Suppl 3():1-10. PubMed ID: 12457421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug development costs when financial risk is measured using the Fama-French three-factor model.
    Vernon JA; Golec JH; Dimasi JA
    Health Econ; 2010 Aug; 19(8):1002-5. PubMed ID: 19655335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Financial effects of pharmaceutical price regulation on R&D spending by EU versus US firms.
    Golec J; Vernon JA
    Pharmacoeconomics; 2010; 28(8):615-28. PubMed ID: 20617857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Costs of Drug Development and Research and Development Intensity in the US, 2000-2018.
    Sertkaya A; Beleche T; Jessup A; Sommers BD
    JAMA Netw Open; 2024 Jun; 7(6):e2415445. PubMed ID: 38941099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decline in economic returns from new drugs raises questions about sustaining innovations.
    Berndt ER; Nass D; Kleinrock M; Aitken M
    Health Aff (Millwood); 2015 Feb; 34(2):245-52. PubMed ID: 25646104
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estimating the cost of new drug development: is it really 802 million dollars?
    Adams CP; Brantner VV
    Health Aff (Millwood); 2006; 25(2):420-8. PubMed ID: 16522582
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How Much Does It Cost to Research and Develop a New Drug? A Systematic Review and Assessment.
    Schlander M; Hernandez-Villafuerte K; Cheng CY; Mestre-Ferrandiz J; Baumann M
    Pharmacoeconomics; 2021 Nov; 39(11):1243-1269. PubMed ID: 34368939
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Financial risk of the biotech industry versus the pharmaceutical industry.
    Golec J; Vernon JA
    Appl Health Econ Health Policy; 2009; 7(3):155-65. PubMed ID: 19799470
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The investment of pharmaceutical industry in hospital clinical research: an estimate for france in 2010].
    Fagnani F
    Therapie; 2012; 67(2):89-96. PubMed ID: 22850096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Returns on research and development for 1990s new drug introductions.
    Grabowski H; Vernon J; DiMasi JA
    Pharmacoeconomics; 2002; 20 Suppl 3():11-29. PubMed ID: 12457422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Innovating by developing new uses of already-approved drugs: trends in the marketing approval of supplemental indications.
    DiMasi JA
    Clin Ther; 2013 Jun; 35(6):808-18. PubMed ID: 23726388
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 54.